. Domain names and their acronyms.
Following bioinformatic quality control (QC) and data analysis (Extended Data Fig. 2-5 ), we identified 172,005,610 short variants, of which 157,411,228 (91.5%) were single nucleotide variants (SNVs) and 14,594,382 (8.5%) were indels up to 50bp long. 48.6% and 40.8% of the SNVs and indels, respectively, were absent from all major variant databases ( Fig. 1e ). 54.8% of the variants were observed in only one family, of which 82.6% were novel. Only 9.08% of novel variants were observed in more than one unrelated individual, typically in sets of individuals with recent common ancestry (Fig. 1f ). SNVs and indels common in our dataset were well represented in genetic databases but, in accordance with theory, the vast majority of the variants we observed were very rare and most were uncatalogued. We called 24,436 distinct large deletions (>50bp) by synthesising inferences from two algorithms across individuals. We also called more complicated types of structural variant, such as inversions, but evidence could not be reliably aggregated across individuals (Supplementary Information). We used the WGS data to determine that only 13 (0.1%) individuals had non-standard sex chromosomal karyotypes (Extended Data Fig. 3 ). Using the high quality variant calls, we inferred a wide range of bioinformatically estimated family sizes, in keeping with differences in enrolment strategies (Supplementary Information), of which most comprised singletons ( Fig. 1d ).
We issued clinical reports for 1,107 distinct causal variants (733 SNVs, 263 indels, 104 large deletions, 6 other structural variants) affecting 304 genes. Of those which were SNVs or indels, 299 (30.0%) were absent from the Human Gene Mutation Database (HGMD). We identified strong evidence (posterior probability (PP) > 0.75) for 99 genetic associations between rare variants and groupings of patients with similar phenotypes using the Bayesian genetic association method, BeviMed 4 . Of these 99 associations, 61 are consistent with firmly established evidence and a further 18 have been reported in the literature since 2015, either by us or by other researchers. We also showed that genetic associations with the extremes of a quantitative trait can identify genes in which mutations cause Mendelian pathologies. Finally, we used a novel method, RedPop, to call cell-type specific regulatory elements (REs) from open chromatin and histone modification data. We combined these calls with cell-type specific transcription factor binding information to identify four pathological rare non-coding variants that cause disease by disrupting the proper regulation of gene expression.
Summary of clinical findings
For each of the 15 rare disease domains, we established a list of diagnostic-grade genes (DGGs) and lists of their corresponding transcripts on the basis of the scientific literature (Supplementary Information). The number of DGGs for each domain ranged from two for Intrahepatic Cholestasis of Pregnancy (ICP) to 1,423 for Neurological and Developmental Disorders (NDD). The DGGs lists were not mutually exclusive because defects of some genes manifest as distinct pathologies compatible with the enrolment criteria of multiple domains (Fig. 2c) . A set of 12 multidisciplinary teams (MDTs) with domain-specific expertise examined the rare variants observed in DGGs in the context of the HPO phenotypes of the carriers. They categorised a subset of the variants as pathogenic or likely pathogenic following standard guidelines 5 and assessed their allelic contribution to disease as full or partial. A conclusive molecular diagnosis was returned for 1,140 of the 7,065 (16.1%) patient records reviewed and those diagnoses featured 1,106 unique causal variants. One quarter of the reports featured variants in BMPR2, ABCA4 and USH2A and a further quarter featured variants in a group of 18 DGGs. The remaining half of the clinical reports concerned variants spread across 306 DGGs, which often featured in a single report ( Fig. 2d , Extended Data Fig. 6 ). The diagnostic yield by domain ranged from three patients out of 184 (1.6%) for Primary Membranoproliferative Glomerulonephritis (PMG) to 391 patients out of 725 (53.9%) for Inherited Retinal Disease (IRD). The variability of diagnostic yield was attributable to heterogeneity in: phenotypic and genetic pre-screening before enrolment, the genetic architecture of diseases and prior knowledge of genetic aetiologies. However, clinical reporting was enhanced by the use of clinical-grade WGS instead of whole-exome sequencing (WES). Of the 955 SNVs and indels in clinical reports, 96 had insufficient coverage in aggregated WES data (Extended Data Fig. 7 ) 6 . For example, a causal SNV encoding a start loss of HPS6 in a case with Hermansky-Pudlak syndrome was identified by WGS but not identified by WES prior to the study. Similarly, deletions spanning only a few exons or part of a single exon are not reliably called by WES and we reported 104 unique large deletions between 203bp and 16.80Mb in length (mean 786.33Kb; median 15.91Kb) 7, 8 .
Our recent genetic discoveries have informed treatment decisions: 27 patients with early-onset dystonia due to variants in KMT2B can be treated by deep brain stimulation 9 ; cases with DIAPH1related macrothrombocytopenia and deafness 10 can have their platelet count restored to a safe level in a preoperative setting with Eltrombopag 11 ; and a case of severe thrombocytopenia accompanied by myelofibrosis and bleeding caused by a gain-of-function variant in SRC 12 was cured by an allogeneic haematopoietic stem cell transplant. In addition, our diagnoses have helped stratify patient care: patients with Primary Immune Disorders (PID) due to variants in NFKB1, which we have shown are the commonest monogenic cause of combined variable immunodeficiency (CVID) 13 , have unexplained splenomegaly and an increased risk of cancer; 27 cases from the Bleeding, Thrombotic and Platelet Disorders (BPD) domain with isolated thrombocytopenia caused by variants in ANKRD26, ETV6 or RUNX1 have an increased risk of malignancy 14, 15, 16 compared to 19 cases with benign thrombocytopenia due to variants in ACTN1, CYCS or TUBB1 17 ; and the prognosis for patients with Pulmonary Arterial Hypertension (PAH) caused by mutations in ATP13A3, AQP1, GDF2 and SOX17, genes which we have recently reported as aetiological 18 , is better than the prognosis for patients with mutations in BMPR2 19 or EIF2AK4 20 .
Quantitative intermediate phenotypes can contain information that is useful for understanding genetic aetiology in difficult to diagnose patients. We examined WGS read alignments for patients with complete absence of a protein encoded by a DGG but carrying an explanatory variant call on only one haplotype. Two patients with a severe unexplained bleeding disorder due to a lack of the αIIbβ3 integrin on their platelet membranes carried two different complex variants in intron 9 of ITGB3: a tandem repeat and an SVA retrotransposon which was not called by either of the two structural variant callers we employed, but was discernible due to an excess of improperly mapped reads (Extended Data Fig. 8a-e ). The third patient had an absence of RhD and RhCE proteins on the membrane of her red cells leading to severe haemolytic anemia. This was due to a large tandem repeat in RHAG, which encodes the Rh-associated glycoprotein (Extended Data Fig. 8f ).
Discovery of rare variants associated with rare diseases
Several cases with similar aetiologies are typically needed to make a novel discovery in rare disease genetics. Cases can be aggregated across siloed studies, using services such as Matchmaker Exchange (MME) 21 . We used MME to identify novel aetiologies for SLC18A2 and WASF1 (Supplementary Information). However, in the context of a study of a unified healthcare system, it is possible make discoveries by statistical analyses of large patient collections.
We applied the statistical method BeviMed 4 to identify genetic associations between gene loci and rare diseases under various modes of Mendelian inheritance (Supplementary Information). We defined a set of phenotypic tags for each domain to determine a set of case/control groupings for BeviMed. Groups of cases were assigned the same tag if their phenotypes were a priori judged compatible with a shared genetic aetiology of disease (Supplementary Table 3 ). The number of unrelated cases in each tag group ranged from three for Roifman syndrome to 1,101 for PAH. For each gene-tag pair, we compared the genotypes at rare variant sites between unrelated individuals with the tag (cases) and unrelated individuals without the tag (controls). We considered a PP of association greater than 0.75 to be strong evidence supporting a genetic aetiology. Additionally, for each analysis BeviMed inferred a conditional PP over the mode of inheritance, a conditional PP over the molecular consequence class of variants mediating disease risk (e.g. 5' UTR variants or predicted loss-of-function variants) and conditional PPs of pathogenicity for each specific variant. These quantities were used to compare established to inferred modes of inheritance and to estimate the number of cases attributable to variants in each gene 4 .
We inferred strong evidence for association between 29 phenotypic tags, spanning nine domains, and 99 genes. These included 62 established DGGs, 18 DGGs discovered since 2015 18, 22, 23, 24, 25, 26, 13, 27, 28, 29, 8, 17, 30, 31, 25, 32, 9, 33, 10 and 19 candidates requiring further investigation ( Fig. 3 ). Thus, 80 of 99 genetic associations are confirmed. We estimated that 606.6 cases are attributable to rare variants contributing to the 80 confirmed associations, 94.8 of which were attributable to the association between variants in BMPR2 and PAH. For one gene (GP1BB), the mode of inheritance inferred by BeviMed differed from that established in the literature, challenging longheld assumptions 29 . These results show that a unified analysis of standardised homogeneously collected genetic and phenotypic data from large cohorts of different rare disease domains is a powerful approach for genetic discovery.
Rare variants associated with extremes of a quantitative trait in UK Biobank
Several rare diseases (e.g. familial hypercholesterolaemia, CVID, thrombocytopenia, von Willebrand disease) are diagnosed and clinically characterised by reference to a quantitative trait that acts as a causal intermediate (or close proxy) for pathology and symptoms. Mutationselection equilibrium ensures strong negative selection in the tails of heritable quantitative traits, so individuals in the extreme tails should have lower fecundity, perhaps due to greater risk of disease. We sought to identify genes likely to carry mutations causing RBC pathologies by computing a univariate quantitative summary of baseline RBC full blood count (FBC) traits in the UK Biobank participants of European ancestry. We aimed to develop a score capturing as much rare-variant heritability as possible. To achieve this, we used the joint distribution of GWASestimated effect sizes for associations between variants with MAF < 1% and four mature RBC FBC traits as a model for the effect of causal rare alleles identified by WGS 34 (Fig 4a) . We successfully sequenced 764 participants, 383 of which were extreme for the left tail of the score, representing a low RBC count (RBC#) and a high mean cell volume (MCV), and 381 of which were extreme for the right tail of the score, representing a high RBC# and a low MCV (Fig. 4b,c ).
We treated each of the two tail groups as a set of cases in a BeviMed analysis, identifying 12 genes showing stronger evidence for association than the moderate PP threshold 0.4 ( Fig. 4d ). HBB and TFRC can be considered positive controls, as they are known to carry mutations causing Mendelian microcytic anaemias. Other genes, including CUX1 and ALG1 are biologically plausible candidates. These results (Supplementary Table 3 ) indicate that the analysis of quantitative extremes in apparently healthy population samples may identify medically relevant loci unidentified by GWAS for quantitative traits 34, 35 .
Aetiological variants in regulatory elements
Recent statistical modelling suggests that only a small proportion of the burden of heritable neurodevelopmental disorders can be attributed to de novo pathogenic SNVs in non-coding elements 36 . Nevertheless, rare variants in REs are known to cause disease by disrupting transcription or translation 37, 38, 39 . We searched for aetiological variants in the REs of 246 DGGs implicated in recessive haematopoiesis-related disorders. Firstly, we defined a set of active REs we named a 'regulome' for each of six blood progenitor and mature blood cell types. We achieved this by merging transcription factor binding sites identified by ChIP-seq with genomic regions called by RedPop, a new detection method exploiting the anti-covariance of ATAC-seq and H3K27ac ChIP-seq coverage in REs (Supplementary Information). We linked the REs to genes on the basis of genomic proximity and promoter capture Hi-C data 40 . Secondly, we assigned each regulome to one or more of the BPD, PID and Stem Cell and Myeloid Diseases (SMD) domains, depending on the relevance of the corresponding cell types to these domains ( Supplementary  Table 3 ). Finally, we searched for cases carrying a rare homozygous or hemizygous deletion of an RE active in a cell type assigned to the domain of the case and which was linked to a DGG of that domain. We also searched for heterozygous deletions meeting these criteria that were in compound heterozygosity with a rare coding variant in a DGG linked to the deleted element ( Fig.  5a ). This explained three cases: a PID patient carrying a deletion overlapping the 5' UTR region of ARPC1B in compound heterozygosity with a frameshift variant in the same gene (Thaventhiran et al, under review), a nine year old boy with autism spectrum disorder and thormbocytopenia carrying a hemizygous deletion of a GATA1 enhancer on the X chromosome, and a male with several autoimmune-mediated cytopenias carrying a homozygous deletion of intronic CTCF binding sites 41 of LRBA.
The X-linked deletion in the autistic boy (Extended Data Fig. 9a -b) removed an element regulating GATA1 as well as exons 1-4 of HDAC6. He had a persistently low platelet count (52x10 9 /l; normal range 150x10 9 /l-450x10 9 /l) and a mean platelet volume in the 99.9 th percentile of the distribution for UK Biobank males ( Fig. 5b ) 42 . Electron microscopic imaging of his platelets showed reduced α-granule content (Extended Data Fig. 9c-e ). Culture of the child's stem cells recapitulated ineffective formation of platelets by megakaryocytes (Extended Data Fig. 9f -k). Macrothrombocytopenia, reduced α-granule content and ineffective platelet formation are all characteristic of patients with pathogenic coding mutations of GATA1 43, 28082341). His platelets contained reduced GATA1 (Fig. 5g ), consistent with reduced transcription due to deletion of the GATA1 enhancer 44 . HDAC6 is the major deacetylase for removing the acetyl group from Lys40 of α-tubulin, which is located in polymerized microtubules 45 . The absence of HDAC6 in the child was accompanied by extremely high expression levels of acetylated α-tubulin in his platelets ( Fig.  5e ), concordant with observations of Hdac6 knockout mice 46 . This aberrant acetylation is associated with bleeding 46 and altered emotional behaviour 47 in mice. Thus, the reduced expression of GATA1 and the absence of HDAC6 jointly cause a new syndrome of macrothrombocytopenia accompanied by neurodevelopmental problems.
The patient with a homozygous deletion of a CTCF binding site in the first intron of LRBA (Fig.  5h ) presented with a pancytopenia, characterised mostly by neutropenia and anaemia, and complicated by periods of thrombocytopenia. These cytopenias were mediated by autoantibodies due to a loss of tolerance for multiple autoantigens, which is characteristic of patients with reduced LRBA function 48 .
We adapted our approach to solving cases caused by non-coding deletions to search for noncoding SNVs with a CADD 49 score > 20, in the presence of a high-impact coding variant in compound heterozygosity in the assigned DGG. This approach identified two potentially aetiological SNVs in elements assigned to AP3B1 and MPL, and we studied the 10 year old male patient carrying the latter mutation in more detail. MPL encodes the receptor for the megakaryocyte growth factor thrombopoietin 50 . Loss of MPL causes chronic amegakaryocytic thrombocytopenia in humans 51 and Mpl knockout mice have severe thrombocytopenia 52, 53 . The SNV (chr1:43803414 G>A) was in an RE detected by RedPop, the activity of which is specific to megakaryocytes in blood cell physiology ( Fig. 5i ), had a CADD score of 21.8, was absent from gnomAD, and was in compound heterozygosity with a deletion of exon 10 of MPL, which was inherited from the patient's mother (Extended data, Fig. 10a ,b,c). As a result, platelet MPL levels were significantly reduced in the patient compared to controls (Extended data, Fig. 10d ), suggesting MPL transcription on the haplotype inherited from the father is less efficient, probably because of disruption to a binding site for the transcription factor HIF1A. In contrast to MPL-null patients 54 , who are extremely thrombocytopenic because their bone marrow is almost devoid of megakaryocytes and eventually suffer haematopoietic stem cell exhaustion, this 10 year old boy had platelet counts which stabilised around 45x10 9 /l and a marrow that was only moderately depleted of megakaryocytes. As the regulatory SNV does not abolish MPL completely (Extended Fig. 10c ), the boy has a milder clinical phenotype than MPL-null cases.
Discussion
Before now there has been limited integration between clinical genetic testing services and aetiological studies of rare diseases. We have shown that WGS in a unified national healthcare system can tackle these two objectives concurrently (Fig. 1a ). This synergy can only be achieved if sequencing data from explained cases (Fig. 2) , unexplained cases and unaffected individuals are analysed jointly and if consent to contact participants for follow-up studies has been obtained at enrolment. We have demonstrated the utility of data aggregation and sharing through the number of genetic associations we have found across a diversity of rare diseases (Fig. 3 ). This study follows on from large-scale whole-exome and shallow genome sequencing studies in the UK 55, 56 and has been the blueprint for the UK's 100,000 Genomes Project, which recently completed sequencing. We have initiated WGS of UK Biobank participants to study individuals with extreme values for a quantitative phenotype. Extreme trait values may be the result of measurement error, extreme polygenic loads 35 or rare genetic variation and such individuals are typically excluded from GWAS studies. We have shown that genetic associations with the tail of a quantitative distribution can identify genes mediating Mendelian pathologies in the same domain of human biology (Fig. 4) . The forthcoming WGS of 0.5M UK Biobank participants provides an opportunity to study other traits following similar approaches. Finally, we have provided examples of rare variants causing disease by disrupting non-coding REs of the genome. The reliability and affordability of WGS and the availability of cell-type specific epigenetic data make the exploration of the non-coding genome ( 
Methods

Enrolment, research ethics and consent
The NIHR BioResource (NBR) enrolled patients with rare diseases and their close relatives as part of a pilot study for the 100,000 Genomes Project. For this study, 15 rare disease domains were approved after review by the Sequencing and Informatics Committee of the NBR. Enrolment of participants started in December 2012 and was completed in March 2017. In addition, samples from a second rare diseases pilot study, coordinated by Genomics England Ltd (GEL) are included together with a number of control samples and samples from the UK Biobank cohort 57 . The NBR-Rare Diseases study was coordinated by the University of Cambridge. Participants were recruited mainly at NHS Hospitals in the UK, but also at overseas centres (Supplementary Table 1 , Extended Data Fig. 1a ). All 13,187 participants provided written informed consent, either under the East of England Cambridge South national research ethics committee (REC) reference 13/EE/0325 or under alternative REC-approved studies. Obtaining consent for overseas samples was the responsibility of the respective principal investigators at the enrolling hospitals. The NBR retained blank versions of the consent forms from overseas participants and a material transfer agreement was applied to regulate the exchange of samples and data between the donor institutions and the University of Cambridge.
Clinical and laboratory phenotype data Staff at hospitals responsible for enrolment were provided with the eligibility criteria for their respective domains as described above in the domain descriptions. The clinical and laboratory phenotype data were captured through case report forms (CRF) by paper questionnaires or by online CRF data capture applications and deposited in the NBR study database. Online data capture allowed for the entry of Human Phenotype Ontology (HPO) terms 58 by staff at the enrolment centre and data from paper questionnaires were transformed into HPO terms by the study coordination office. Free text entries were transformed into HPO terms where feasible. An overview of the HPO data obtained for the 15 NBR rare disease domains is depicted in Extended Data Fig. 1c,d. DNA sequencing Samples were received as either DNA extracted from whole blood or as whole blood EDTA samples that were extracted at a central DNA extraction and QC laboratory in Cambridge. Samples were tested for adequate concentration (Picogreen), DNA degradation (gel electrophoresis) and purity (OD 260/280 quality control (Trinean)) before selection for WGS. DNA samples were prepared at a minimum concentration of 30 ng/μl in 110 μl, visually inspected for degradation and had to have an OD 260/280 between 1.75 and 2.04. They were then prepared in batches of 96 and shipped on dry ice to the sequencing provider (Illumina Inc, Great Chesterford, UK). Further sample QC was performed by Illumina Inc to ensure that the concentration of the DNA was > 30 ng/ul and that every sample generated high quality genotyping results (Illumina Infinium Human Core Exome microarray). Samples with a repeated array genotyping call rate < 0.99, high levels of cross-contamination, mismatches with the declared gender that could not be resolved by further investigation, or for which consent had been withdrawn, were excluded from WGS (n=59). The genotyping data were also used for positive sample identification and sample identity was verified before data delivery. In short 0.5 μg of the DNA sample was fragmented using Covaris LE220 (Covaris Inc., Woburn, MA, USA) to obtain an average size of 450 base pair (bp) DNA fragments. DNA samples were processed using the Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., San Diego, CA, USA) on the Hamilton Microlab Star (Hamilton Robotics, Inc, Reno, NV, USA). The final libraries were checked using the Roche LightCycler 480 II (Roche Diagnostics Corporation, Indianapolis, IN, USA) with KAPA Library Quantification Kit (Kapa Biosystems, Inc, Wilmington, MA, USA) for concentration. From February 2014 to June 2017 three read lengths were used: 100bp (377 samples), 125bp (3,154 samples) and 150bp (9,656 samples). Samples sequenced with 100bp and 125bp reads utilised three and two lanes of an Illumina HiSeq 2500 instrument, respectively. Samples sequenced with 150bp reads utilised a single lane of a HiSeq X instrument. At least 95% of the autosomal genome had to be covered at 15X and a maximum of 5% of insert sizes had to be less than twice the read length. Following sample and data QC at Illumina, 13,187 sets of WGS data files were received at the University of Cambridge High Performance Computing Service (HPC) for further QC.
WGS data processing pipeline
The WGS data for the 13,187 samples returned by the sequencing provider underwent a series of processing steps (Extended Data Fig. 2 ), described in detail in the Supplementary Information. Briefly, the samples were sex karyotyped and pairwise kinship coefficients were computed. This information was used to check for repeat sample submissions and sample swaps. Additionally, four further QC checks were applied to ensure the SNVs and short insertions/deletions (indels) were of a high standard. Overall, 150 samples (1.1%) were removed, leaving a dataset of 13,037 samples for downstream analysis. The 13,037 individuals were assigned one of the following ethnicities: European, African, South Asian, East Asian or Other. Pairwise relatedness adjusted for population stratification was then computed and used to generate networks of closely related individuals and to define a maximal set of 10,259 unrelated individuals. The variants in the 13,037 individuals were left-aligned and normalised with bcftools, loaded into our HBase database and filtered on their overall pass rate (OPR), defined in Supplementary Information. The sex karyotypes, the ethnicities and the relatedness estimates were used, along with enrolment information, to annotate the samples and variants. Samples were annotated with: affected/unaffected status, membership of the set of probands, membership of the maximal unrelated set, ethnicity and sex karyotype. Variants were annotated with CellBase consequence predictions, HGMD information where available and population-specific allele frequencies.
Pertinent findings For each of the 15 rare disease domains (i.e. all domains except UKB, CNTRL and GEL) a gene list was generated by domain-specific experts. Genes were included in the lists if there was a high enough level of evidence in the literature for gene-disease association. The 2,497 gene/domain pairs, encompassing 2,073 unique genes across all domains, were manually curated and annotated with the relevant RefSeq and/or Ensembl transcript identifiers to support variant reporting. Transcripts were selected based on, by order of priority, community input, presence in the Locus Reference Genomic (LRG) resource 59 or designation as canonical in Ensembl. Variants (SNVs, indels) were shortlisted if (i) their MAF in control populations 6 was < 1/1,000 for putative novel causal variants and < 25/1,000 for variants listed as disease-causing in HGMD, (ii) their predicted impact according to the Variant Effect Predictor 60 was "HIGH" or "MODERATE" or if the consequences with respect to the designated transcript included one of "splice_region_variant" or "non_coding_transcript_exon_variant" if the variant was in a non-coding gene, (iii) the variant affected a gene relevant to the patient's disease. Variants with more than 3 alleles or a MAF >= 10% in the diseases cohort were discarded to, respectively, guard against errors in repetitive regions and remove potential systematic artefacts. The above filtering criteria were applied universally to all domains, except for ICP which adopted a higher MAF threshold of 3% for both novel and previously reported variants. The higher threshold accounted for causal variants being present in the male and non-child bearing female population. This strategy reduced the number of variants for review by the MDT from about 4 million per person to fewer than 10, while confidently retaining known regulatory or moderately common pathogenic variants. For each affected participant with prioritised variants, the variant calls, HPO-coded phenotype and the relevant metadata (unique study numbers; referring clinician and hospital; selfdeclared and genetically inferred gender, ancestry, relatedness, and consanguinity level) were transferred to Congenica Inc (Cambridge, United Kingdom) for visualisation in the Sapientia TM web application during MDT meetings. MDTs brought together experts from different hospitals across the UK and abroad, and typically consisted of an experienced clinician with domainspecific knowledge, a scientist with experience in clinical genomics, a clinical bioinformatician and a member of the reporting team. Assignment of the level of pathogenicity followed the American College of Medical Genetics guidelines 5 and variants (V) were marked in Sapientia TM as pathogenic, likely pathogenic or of unknown significance (VUS). Only pathogenic and likely pathogenics ones were systematically reported and VUSs were reported at the MDT's discretion. As per REC-approved study protocol, secondary findings (e.g. breast cancer pathogenic variants in BRCA1 in patients not presenting with this phenotype) were not reported.
Genetic association testing in genes
We used the BeviMed statistical method 4 to identify genetic associations with rare diseases in our dataset. Each run of BeviMed requires the definition of a set of cases and controls, all of which should be unrelated with each other, and a set of rare variants to include in the inference. To achieve adequate power, the cases should be chosen such that they potentially share a common genetic aetiology (e.g. because the phenotypes are similar) and the rare variants should be chosen such that they potentially share a mechanism of action on phenotype (e.g. because they are predicted to have a similar effect on a particular gene product). BeviMed computes PP values of no association, dominant association and recessive association and, conditional on dominant or recessive association, it computes the PP that each variant is pathogenic. We can impose a prior correlation structure on the pathogenicity of the variants that reflects competing hypotheses as to which class of variant is responsible for disease. These classifications typically group variants by their predicted consequences. The class of variant responsible can then be inferred by BeviMed, thereby suggesting a particular mechanism of disease. The methodology is described in further detail in Supplementary Information and in reference 4 .
Regulome analysis
We applied the BLUEPRINT protocol for ChIP-seq data analysis (http://dcc.blueprint-epigenome.eu/#/md/chip_seq_grch37). We defined regulomes for activated CD4+ T cells (aCD4), B cells (B), erythroblasts (EB), megakaryocytes (MK), monocytes (MON) and resting CD4+ T cells (rCD4). For each cell type, we used open chromatin data (ATAC-seq or DNAse-seq) and histone modification data (H3K27ac) to identify REs using the RedPop method (see below). Additionally, for MK and EB, we had access to the following transcription factor (TF) ChIP-seq data, which were used to call peaks (see below) and supplement the regulomes: FLI1, GATA1, GATA2, MEIS1, RUNX1, TAL1 and CTCF for MK; GATA1, KLF1, NFE2 and TAL1 for EB; and CTCF for MON and B. For each cell type, the regulome build process proceeded as follows: 1. Call RedPop regions using ATAC-seq/DNAse-seq and H3K27ac-seq data; 2. Call TF/CTCF binding peaks using ChIP-seq data if available and obtain enrichment scores; 3. Discard TF regions with an enrichment score < 10 unless they overlap between at least two different TFs; 4. Collapse overlapping features to obtain a single genomic track; 5. Merge features within 100bp of each other. Each regulome feature was assigned a gene label using either gene annotations from Ensembl (v75) or a compendium of previously published promoter capture Hi-C data (pcHi-C) 40 as follows: 1. Assign to a gene if the feature overlaps the gene or the region up to 10Kb either side of the gene body; 2. Assign to a gene if the feature overlaps the gene's pcHi-C 'blind' spot. This region is defined by three HindIII restriction fragments, incorporating the capture fragment overlapping target gene TSS, and 5' and 3' adjacent fragments; 3. Assign to a gene if the feature overlaps a linked promoter interacting region identified using pcHi-C in the same cell type.
Functional analysis of the GATA1 enhancer/HDAC6 deletion The GATA1 enhancer/HDAC6 deletion was confirmed by PCR using primers HDAC6-F: 5'-catcttcaagaggatcagagg and HDAC6-R: 5'-catagctagacactggtt. Electron microscopy for platelets was performed as described 43 . Immunostaining of resting and fibrinogen spread platelets was performed as described 33 and analyzed by Structured Illumination Microscopy (SIM, Elyra S.1, Zeiss, Heidelberg, D.E). Total protein lysates were obtained from platelets for immunoblot analysis as described 61 . The following antibodies were used for SIM and immunoblot analysis: rabbit anti-HDAC6 (clone D2E5, Cell Signaling technology, Danvers, MA, USA), mouse anti-acetylated tubulin antibody (clone 6-11B-1, Sigma, St Louis, MO, USA), mouse anti-alpha-tubulin (A11126, Thermo Fisher Scientific, Waltham, MA, USA), rabbit anti-VWF (Dako, Aligent Technologies, Leuven, BE), mouse anti-CD63 and rat anti-GATA1 N6 (Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-GATA1 (NF that was produced against recombinant N-terminal zinc finger 62 , rabbit anti-GAPDH (14C10, Cell Signaling) and anti-β3 integrin (sc-14009; Santa Cruz Biotechnology).
MPL expression on platelets
The level of MPL protein on the platelet membrane was measured by flow cytometry (Beckman Coulter FC500) using the monoclonal antibodies: APC-labelled IgG1 against CD42b (clone HIP1, BD Pharmingen, number: 551061), PE-labelled IgG1 against CD110 (clone REA250, Miltenyi Biotec) and a PE-labelled isotype control (clone MOPC-21, BD Pharmingen, number: 555749). In short, a sample of EDTA anticoagulated blood was incubated with anti-CD110 (or control) and anti-CD42b for 30 minutes. Mean fluorescence intensity (MFI) produced by the anti-CD110 was measured by flow cytometry on cells gated on the CD42b APC signal, side and forward scatter. Nanopore sequencing Oxford Nanopore-based sequencing of long-range PCR-amplified target DNA was performed as previously described 63 with the aim to resolve the genetic architecture of intron 9 of ITGB3 in a case with Glanzmann's thrombasthenia. The flow cell ran for 3 hours, and the mean coverage was 863,986X.
Code availability Code to run HBASE is available from https://github.com/mh11/VILMAA. The RedPop software package is available from https://gitlab.haem.cam.ac.uk/et341/redpop/.
Data availability
Genotype and phenotype data will become available from the day that the manuscript has been published in a peer-reviewed journal. It is expected that the manuscript may have been through peer review and revision before September 2019 but this could be also at a later date. The data access procedures outlined below will NOT be active until the date of publication.
The genotype and phenotype data from the 4,835 participants enrolled in the NIHR BioResource for the 100,000 Genomes Project-Rare Diseases Pilot can be accessed by seeking access via Genomics England Limited following the procedure outlined at: https://www.genomicsengland.co.uk/about-gecip/joining-research-community/ The genotype data for the 764 UK Biobank samples will be made available through a data release process overseen by UK Biobank (https://www.ukbiobank.ac.uk/). The phenotype data from UK Biobank participants are available from UK Biobank using their normal access procedures. The genotype data from the vast majority of the remaining 7,438 NIHR BioResource participant has been deposited in European Genome-phenome Archive (EGA) at the EMBL European Bioinformatics Institute. Deposition of genotype at EGA is grouped by rare disease domain: EGA accession codes: BPD: EGAD00001004519, CSVD: EGAD00001004513, HCM: EGAD00001004514, ICP: EGAD00001004515, IRD: EGAD00001004520, MPMT: EGAD00001004521, NDD: EGAD00001004522, NPD: EGAD00001004516, PAH: EGAD00001004525, PID: EGAD00001004523, PMG: EGAD00001004517, SMD: EGAD00001004524, SRNS: EGAD00001004518. Genotype data will be available at the time of publication from EGA under the principles of obtaining access to data, which are controlled by a Data Access Committee (DAC) (https://www.ebi.ac.uk/ega/). Access to more detailed phenotypic datasets on the vast majority the 7,438 NIHR BioResource participants can be requested by completing the NIHR BioResource Data Access Agreement application (dac@bioresource.nihr.ac.uk). Decisions about granting access are controlled by a DAC. A DAC has the full right to not approve requests for access to data and is under no obligation to provide reasons for a refusal. The DAC will in reaching its decisions about granting right of access to data respect the agreement with the study participants as set out in their signed consent.
The ATAC-seq and H3K27ac ChIP-seq data to support the generation of the regulomes are available from GEO or EGA, or referenced to their publication as follows. H3K27ac ChIP-seq: aCD4 64 , B (ERR1043004, ERR1043129, ERR928206, ERR769436), EB (EGAD00001002377), MK (EGAD00001002362), MON (ERR829362 (ERS257420), ERR829412 (ERS222466), ERR493634 (ERS214696)), rCD4 64 . ATAC-seq: aCD4 (accession will be available before publication), B (SRR2126769 (GSE71338)), EB (SRR5489430 (GSM2594182)), MK (EGAD00001001871), MON (accession number requested), rCD4 (GEO accession will be available before publication).
MDT-reported alleles and their clinical interpretation have been deposited with ClinVar (accession number will be available before publication) and also with DECIPHER (accession will be available before publication).
University of Cambridge and GEL, respectively. Additional funding was provided by the BHF, MRC, NHS England, the Wellcome Trust and many other fund providers (also see Funding acknowledgment for individual researchers). The pilot studies use data provided by patients and their close relatives and collected by the NHS and other healthcare providers as part of their care and support. The vast majority of participants in the two pilot studies have been enrolled in the NIHR BioResource. We thank all volunteers for their participation, and also gratefully acknowledge NIHR Biomedical Research Centres, NIHR BioResource Centres, NHS Trust Hospitals, NHS Blood and Transplant and staff for their contribution. This research has been conducted using the UK Biobank Resource under Application Number 9616, granting access to DNA samples and accompanying participant data. UK Biobank has received funding from the MRC, Wellcome Trust, Department of Health, British Heart Foundation (BHF), Diabetes UK, Northwest Regional Development Agency, Scottish Government, and Welsh Assembly Government. The MRC and Wellcome Trust played a key role in the decision to establish UK Biobank. Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or of the any other funding agencies.
